» Articles » PMID: 17583556

Mirk/Dyrk1B in Cancer

Overview
Journal J Cell Biochem
Date 2007 Jun 23
PMID 17583556
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Mirk/Dyrk1B is a member of a conserved family of serine/threonine kinases which are activated by intramolecular tyrosine phosphorylation, and which mediate differentiation in different tissues-Mirk in skeletal muscle, Dyrk1A in the brain, etc. One role of Mirk in skeletal muscle differentiation is to block cycling myoblasts in the G0 quiescent state by modification of cell cycle regulators, while another role of Mirk is to limit apoptosis in fusing myoblasts. Amplification of the Mirk gene, upregulation of Mirk expression and/or constitutive activation of this kinase have been observed in several different types of cancer. If coupled with a stress condition such as serum starvation which induces a quiescent state, depletion of Mirk by RNA interference using either synthetic duplex RNAi's or pSilencer-encoded RNAi's have decreased colony formation of different cancer cell lines and enhanced apoptosis induced by chemotherapeutic drugs. Mirk is activated by phosphorylation by the stress-activated SAPK kinases MKK3 and MKK6. Our working hypothesis is that Mirk is activated by this pathway in response to various stresses, and then acts as a checkpoint kinase to arrest damaged tumor cells in a quiescent state and allow cellular repair. Pharmacological inhibition of Mirk may enhance the anti-tumor effect of chemotherapeutic drugs.

Citing Articles

DYRK4 upregulates antiviral innate immunity by promoting IRF3 activation.

Zeng X, Xu J, Liu J, Liu Y, Yang S, Huang J EMBO Rep. 2024; 26(3):690-719.

PMID: 39702801 PMC: 11811199. DOI: 10.1038/s44319-024-00352-x.


Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.

Sester S, Wilms G, Ahlburg J, Babendreyer A, Becker W BMC Cancer. 2024; 24(1):1341.

PMID: 39482615 PMC: 11529244. DOI: 10.1186/s12885-024-13057-0.


-Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents.

Mostafa N, Chen P, Darwish S, Su Y, Shiao M, Piazza G Cancers (Basel). 2024; 16(11).

PMID: 38893153 PMC: 11171218. DOI: 10.3390/cancers16112033.


Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.

Kokkorakis N, Zouridakis M, Gaitanou M Pharmaceutics. 2024; 16(4).

PMID: 38675189 PMC: 11053710. DOI: 10.3390/pharmaceutics16040528.


Mirk/Dyrk1B controls ventral spinal cord development via Shh pathway.

Kokkorakis N, Douka K, Nalmpanti A, Politis P, Zagoraiou L, Matsas R Cell Mol Life Sci. 2024; 81(1):70.

PMID: 38294527 PMC: 10830675. DOI: 10.1007/s00018-023-05097-9.